中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2014年
17期
2561-2563
,共3页
动脉粥样硬化%颈动脉疾病%医学,中国传统
動脈粥樣硬化%頸動脈疾病%醫學,中國傳統
동맥죽양경화%경동맥질병%의학,중국전통
Atherosclerosis%Carotid artery diseases%Medicine,Chinese traditional
目的:观察化瘀通脉方对颈动脉粥样硬化斑块的临床疗效。方法将102例颈动脉粥样硬化斑块形成的患者,按照随机数字表法分为对照组和观察组,每组各51例,对照组予辛伐他汀治疗,观察组予中药化瘀通脉方治疗,治疗前后检测颈动脉内径( CAD)、颈动脉内膜中层厚度( IMT)、斑块体积、搏动指数( PI)和血脂水平,并进行临床疗效及不良反应的评价。结果治疗3个月后,观察组临床症状明显改善, CAD增加、IMT变薄、斑块体积缩小、PI改善(t=11.22、7.21、26.25、6.87,均P<0.05),血脂水平(TG、TC、HDL-C、LDL-C)及动脉硬化指数(AI)均明显改善(t=8.24、13.69、6.85、9.53、17.50,均P<0.05),与对照组治疗后比较差异均无统计学意义(t=0.97、1.83、0.65、1.43、1.86、1.88、1.42、1.85、1.14,均P>0.05),但优于对照组。结论化瘀通脉方对颈动脉粥样硬化斑块的临床疗效与辛伐他汀相当,能调节血脂代谢,并在一定程度上消散及稳定患者颈动脉粥样硬化斑块。
目的:觀察化瘀通脈方對頸動脈粥樣硬化斑塊的臨床療效。方法將102例頸動脈粥樣硬化斑塊形成的患者,按照隨機數字錶法分為對照組和觀察組,每組各51例,對照組予辛伐他汀治療,觀察組予中藥化瘀通脈方治療,治療前後檢測頸動脈內徑( CAD)、頸動脈內膜中層厚度( IMT)、斑塊體積、搏動指數( PI)和血脂水平,併進行臨床療效及不良反應的評價。結果治療3箇月後,觀察組臨床癥狀明顯改善, CAD增加、IMT變薄、斑塊體積縮小、PI改善(t=11.22、7.21、26.25、6.87,均P<0.05),血脂水平(TG、TC、HDL-C、LDL-C)及動脈硬化指數(AI)均明顯改善(t=8.24、13.69、6.85、9.53、17.50,均P<0.05),與對照組治療後比較差異均無統計學意義(t=0.97、1.83、0.65、1.43、1.86、1.88、1.42、1.85、1.14,均P>0.05),但優于對照組。結論化瘀通脈方對頸動脈粥樣硬化斑塊的臨床療效與辛伐他汀相噹,能調節血脂代謝,併在一定程度上消散及穩定患者頸動脈粥樣硬化斑塊。
목적:관찰화어통맥방대경동맥죽양경화반괴적림상료효。방법장102례경동맥죽양경화반괴형성적환자,안조수궤수자표법분위대조조화관찰조,매조각51례,대조조여신벌타정치료,관찰조여중약화어통맥방치료,치료전후검측경동맥내경( CAD)、경동맥내막중층후도( IMT)、반괴체적、박동지수( PI)화혈지수평,병진행림상료효급불량반응적평개。결과치료3개월후,관찰조림상증상명현개선, CAD증가、IMT변박、반괴체적축소、PI개선(t=11.22、7.21、26.25、6.87,균P<0.05),혈지수평(TG、TC、HDL-C、LDL-C)급동맥경화지수(AI)균명현개선(t=8.24、13.69、6.85、9.53、17.50,균P<0.05),여대조조치료후비교차이균무통계학의의(t=0.97、1.83、0.65、1.43、1.86、1.88、1.42、1.85、1.14,균P>0.05),단우우대조조。결론화어통맥방대경동맥죽양경화반괴적림상료효여신벌타정상당,능조절혈지대사,병재일정정도상소산급은정환자경동맥죽양경화반괴。
Objective To investigate the clinical effects of Huayutongmai decoction in treating patients with carotid atherosclerotic plaques .Methods Prospectively analyzed 102 cases with carotid atherosclerotic plaques were divided into the control group and observation group according to random number table method ,51 cases were in each group.The patients in the control group were given the Simvastatin Tablet only ,and the patients in the observation group were given the treatment of Huayutongmai decoction .The CAD,IMT,volume of plaque,PI and lipid levels were detected.The clinical efficacy and adverse reaction were observed after treatment of three months .Results After treatment of three months,the CAD,IMT,volume of plaque,PI(t=0.97,1.83,0.65,1.43) and levels of lipid(TG, TC,HDL-C,LDL-C and AI,t=1.86,1.88,1.42,1.85,1.14) of the observation group were better than those of the control group,but with no significant(all P>0.05).Conclusion Huayutongmai decoction in treating patients with carotid atherosclerotic plaques has better clinical efficacy ,can improve lipid metabolism ,eliminate and stabilize CAS to some extent ,which is worthy of clinical application .